Abeona Therapeutics issues equity awards to attract new non-executive employees

CLEVELAND, Sept. 01, 2026 /CourierPR/ -- Abeona Therapeutics Inc., a biopharmaceutical company developing cell and gene therapies for serious diseases, has announced the issuance of equity awards to new non-executive employees as part of its hiring strategy. The awards, granted in accordance with Nasdaq Listing Rule 5635(c)(4), aim to attract and retain talent.

On August 31, 2026, the Compensation Committee of Abeona's Board of Directors approved the issuance of restricted stock equity awards to five newly hired employees. These awards cover up to 13,300 restricted shares of Abeona common stock. One-third of the shares will vest annually, with the full vesting occurring three years from the grant date, contingent upon continued employment with Abeona.

Abeona Therapeutics, based in Cleveland, Ohio, focuses on developing innovative cell and gene therapies for serious diseases. The company's flagship product, ZEVASKYN® (prademagene zamikeracel), is the first and only autologous cell-based gene therapy for treating wounds in both adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's state-of-the-art cGMP manufacturing facility supports the production of ZEVASKYN, ensuring consistent and high-quality supply.

In addition to ZEVASKYN, Abeona's development portfolio includes ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA, designed to address the limitations of cell therapies in solid tumors. The company's commitment to advancing cell and gene therapies is reflected in its comprehensive pipeline of innovative treatments.